Global Pharmaceutical Contract Manufacturing Market Report 2023-2030

The “Global Pharmaceutical Contract Manufacturing Market – Forecast to 2030” report, recently added to ResearchAndMarkets’s offerings, provides a comprehensive analysis of the pharmaceutical contract manufacturing (PCM) global market.

The market is projected to experience a mid single-digit Compound Annual Growth Rate (CAGR) from 2023 to 2030, ultimately reaching an estimated value of $100,102.8 million by 2030.

Market Growth Factors

1.        Rapid Industry Expansion: The global pharmaceutical market is witnessing rapid growth, driven by factors such as increased research and development, manufacturing advancements, and significant developments in formulation techniques.

2.        Key Market Drivers:

•          Rising global population.

•          Increased prevalence of chronic diseases (e.g., infectious diseases, oncology, cardiovascular disorders).

•          Substantial growth in healthcare spending.

•          Surge in collaborations, mergers, and acquisitions within the pharmaceutical industry.

3.        Role of Contract Manufacturing Organizations (CMOs):

•          Pharmaceutical companies are turning to CMOs to meet growing demand and address challenges.

•          CMOs provide advanced facilities, technologies, and high containment capabilities for manufacturing.

•          Outsourcing to CMOs allows pharmaceutical companies to focus on core strengths and benefit from specialized manufacturing expertise.

4.        Market Segmentation:

•          Contract pharmaceutical manufacturing services primarily focus on Active Pharmaceutical Ingredients (API) and Finished Dosage Formulations (FDF).

Opportunities and Challenges:

1.        Opportunities:

•          Increased outsourcing.

•          High adoption of small molecule drugs across therapeutic areas.

•          Patent expiration and the use of the 505(b)(2) pathway for small molecule drugs.

•          Advanced technologies in API and FDF manufacturing.

•          Rising R&D expenditures.

•          Capacity and capability expansion in advanced Highly Potent APIs and Complex Molecules platforms.

2.        Challenges:

•          Pharmaceutical product contamination (API and FDF).

•          Pricing pressure.

•          Need for highly skilled technicians.

•          Increasing adoption of biologics in disease management.

•          Stringent regulatory policies.

•          Environmental concerns.

Regional Insights:

1.        North America:

•          Largest revenue contributor in 2023.

•          Expected mid-single-digit CAGR growth from 2023 to 2030.

•          Growth drivers include increasing pharma R&D expenditure, new drug developments, approvals of generics, and government support.

2.        Asia-Pacific:

•          Anticipated high single-digit CAGR growth from 2023 to 2030.

•          Key drivers include increasing production of generic pharmaceuticals, extensive manufacturing facilities, and government investments.

•          India plays a significant role with over 3,000 pharmaceutical companies and more than 10,500 manufacturing facilities.

Major Companies

Overview, Financials, Product Portfolio, Key Developments, Business Strategy, SWOT Analysis:

•          Abbvie Inc.

•          Asymchem Laboratories (Tianjin) Co. Ltd

•          Cambrex Corporation

•          Curia

•          Delpharm – Delriv

•          Lonza Group Ltd

•          Porton Pharma Solutions Ltd

•          Recipharm Ab

•          Thermo Fisher Scientific Inc

•          Wuxi Apptec Co. Ltd.

Key Elements of Major Companies Analysis

•          Financial overview.

•          Product portfolio analysis.

•          Key developments in the industry.

•          Business strategy evaluation.

•          SWOT analysis.

The “Global Pharmaceutical Contract Manufacturing Market – Forecast to 2030” report offers a thorough examination of the pharmaceutical contract manufacturing landscape, providing valuable insights for industry stakeholders, investors, and decision-makers. The analysis encompasses market growth factors, opportunities, challenges, regional dynamics, and detailed profiles of major market players.

Related posts:

The Opioid Market Size to Hit $25.3 Billion by 2030 Pharmacovigilance & Drug Safety Software Market to Hit $312 Million by 2030 Global Injectable Drug Delivery Market Projected to Reach USD 58.90 Billion by 2030 Oncology Dominates Active Pharmaceutical Ingredient CDMO Market with 35.5% Revenue Share